Physician profile
Thomas E Kennedy
NPI 1225058951
$1,019.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2021: $29.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $262.74 | 2019 | |
| Emd Serono, INC. | $239.84 | 2019 | |
| Neurocrine Biosciences, INC. | $171.85 | 2019 | |
| Livanova USA, INC. | $94.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.86 | 2019 | |
| Sunovion Pharmaceuticals INC. | $41.01 | 2019 | |
| Ge Healthcare | $34.58 | 2019 | |
| Abbvie INC. | $29.42 | 2021 | |
| Allergan, INC. | $23.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.91 | 2019 | |
| Acadia Pharmaceuticals INC | $12.48 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.49 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.